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Objectives. To determine the importance of acute cardiac events as a cause of mortality compared to non-cardiac events in
the four month period following liver transplantation (LT) using current preoperative cardiac screening strategies. Patients and
Methods. We retrospectively reviewed timing, type, and outcome of adverse cardiac events, and all cause mortality in the 4 month
postoperative period in 393 consecutive LT patients from October 1999 to February 2008. Results. Of 30 total deaths (7.6% overall
mortality rate), 27 (90%) were due to surgical or medical complications and 3 (10%) were primary cardiac deaths (0.8% cardiac
mortality rate). Acute cardiac events occurred in 26 patients (6.6%), including 13 arrhythmias (50%), 7 new onset heart failures
(27%), and 6 myocardial infarctions (23%). Twelve of 13 intraoperative events were arrhythmias (92%) including two of three
cardiac deaths. Conclusions. Using current preoperative screening recommendations, deaths from primary cardiac events within
four months of LT are very uncommon (0.8%), especially compared with deaths related to medical and surgical complications
(6.9%).
1.Introduction
Acute cardiac events such as myocardial infarction, con-
gestive heart failure, and arrhythmias are an important
cause of death in end stage liver disease (ESLD) patients
both at the time of and after liver transplantation (LT).
However,identifyingLTcandidatesatriskforadversecardiac
events remains a challenge. Traditional risk stratiﬁcation
algorithms such as the Framingham Risk Score (FRS) are
poor predictors of cardiac events in the ESLD population
[1]. The American Association for the Study of Liver
Diseases (AASLD) recommends that LT candidates who
are older than 50, diabetic, past or present smokers, or
have a family history of heart disease undergo a cardiac
stress test (dobutamine stress echo (DSE), pharmacologic
nuclear perfusion) or cardiac catheterization to rule out
obstructive coronary artery disease (CAD) [2]. However,
the data to support this recommendation is controversial
[3–6] and whether this strategy is eﬀective in reducing
cardiac events following LT has not been proven. In addition
current evidence [7–9], including our own experience [10],
suggests that serious postcardiac arrhythmias at the time of
donor liver reperfusion and in the postoperative period are
also a major cause of cardiac events following LT. More data
is needed to determine the predisposing factors for acute
cardiac events, as well as the best screening and prevention
methods in patients undergoing liver transplantation.
T h ep r i m a r ya i mo ft h i ss t u d yw a st or e v i e wo u re x p e -
rience over a ten year period to determine the importance
of acute cardiac events as a cause of mortality compared to
noncardiac events at surgery and up to four months after
LT using current cardiac preoperative screening strategies.
Our hypothesis was that in the setting of eliminating nearly
all patients with known CAD, and using myocardial stress
testing to rule out ischemia in the rest, cardiac events and
mortality would be uncommon compared to noncardiac2 Journal of Transplantation
mortality. A secondary aim was to see if asymptomatic
patients <50 years old did not need cardiac screening as
suggested by the AASLD.
2.MaterialsandMethods
Weretrospectivelyreviewedthechartsofall393patientswho
underwent LT at our institution between October 1st, 1999
and February 1st, 2008. Clinical data up to the four months
postsurgery was available in all individuals. Patients were
grouped based on age (<50 or ≥50 years old), the number
of AASLD criterion (0 to 4) for cardiac risk (>50 years old,
diabetes mellitus, current or past history of smoking, or
family history of heart disease), prior history of CAD, and
whether or not they underwent a preoperative cardiac stress
t e s t .T h et y p eo fc a r d i a cs t r e s st e s tp e r f o r m e dw a sn o t e da sa
dobutamine stress echocardiogram (DSE), chemical nuclear
perfusion study, or coronary angiogram. Approval for this
study was obtained by the Mayo Clinic Arizona Institutional
Review Board.
The deﬁnition of “high-risk” patients followed the
AASLD guidelines [2] which included patients ≥50 years
old, those with diabetes, past or present smoking, or with
a family history of heart disease. The medical record and
liver transplant operative report were reviewed for adverse
cardiac events. Adverse cardiac events were deﬁned as new
myocardial infarction (MI) conﬁrmed by serum troponin
T and creatine kinase assays, new onset heart failure with
a reduced LV ejection fraction, or an arrhythmia that
requiredurgenttreatmentbecauseofhemodynamicinstabil-
ity. These arrhythmias included severe bradycardia, asystole,
ventricular tachycardia, or ventricular ﬁbrillation. Serious
adverse cardiac events were also classiﬁed by their timing as
occurring intraoperatively, postoperatively, or in the post-
operative period up to four months after liver transplant.
Noncardiac deaths were deﬁned as deaths not attributable to
a primary cardiac cause but instead to medical or surgical
complications within 4 months of LT. Classiﬁcation of death
as cardiac versus noncardiac was adjudicated independently
by two board-certiﬁed cardiologists. Other clinical variables
assessed included patient demographics and Model for End
Stage Liver Disease (MELD) score.
3.StatisticalAnalysis
Statistical analysis was performed using SAS 9.1.3 software
(SAS institute Inc. Cary, NC). Data are summarized as mean
±SDornumberandpercentage.ChisquareandFisherexact
tests were used to compare pairs of categorical variables.
Absolute and relative risk was calculated for cardiovascular
events in patient groups with 95% conﬁdence intervals
calculated by the exact binomial method.
4. Results
A total of 393 subjects underwent LT and were included in
the analysis. Table 1 summarizes their clinical characteristics
and Table 2 shows their risk factors by age groups. Figure 1
Table 1: Liver transplant patient characteristics.
N = patients 393
Age (years) 52.0 ± 10.1 (range 17–72)
Male 267 (68%)
Diabetes Mellitus 94 (24%)
Hypertension 85 (21%)
History of smoking 240 (58%)
Smoking within 1 year of transplant 89 (23%)
Known Coronary Artery Disease 11 (3%)
MELD score at time of transplant 21 ± 8
Cold Ischemic Time (hours) 5.9 ± 2.5
Etiology of Liver Failure
Hepatitis C 161 (41%)
Alcohol-related cirrhosis 51 (13%)
Hepatocellular carcinoma 50 (12%)
Cryptogenic idiopathic cirrhosis 24 (6%)
Primary sclerosing cholangitis 20 (5%)
Primary biliary cirrhosis 12 (3%)
Other 65 (17%)
MELD: model for end stage liver disease.
depicts the overall mortality, the number and type of adverse
cardiac events, when the events occurred, and their outcome.
Figure 2 shows the number and type of cardiac events and
mortality in the LT patients by their age group of ≤ or > 50
years old. Figure 3 shows the cardiac events by age and risk
factorsandwhethertheyhadapreoperativecardiacstresstest
or angiogram.
InpatientsundergoingLTtherewere30deathswithinthe
ﬁrst four months after surgery for an overall mortality rate of
7.6%. Ninety percent of deaths (27/30) were due to surgical
or medical complications. Figure 1(a) shows that there were
26 adverse cardiac events (6.6%). Three of the 30 total deaths
were cardiac in nature (10%); 2 arrhythmias at the time of
surgery and 1 new heart failure that occurred after hospital
discharge. The overall cardiac mortality rate was very low at
0.8%.
Figure 1(b) shows the timing of the 26 adverse cardiac
events. Twenty ﬁve of 26 events (96%) occurred before
hospital discharge. Thirteen of these events (50%) occurred
at the time of surgery. Twelve of these 13 events were
cardiac arrhythmias (92%) and two patients could not be
resuscitated and expired. There were 7 cases of new onset
heart failure and 6 small non-Q wave myocardial infarctions
by cardiac biomarker rise. The single patient who had an
adverse cardiac event after hospital discharge developed new,
severe heart failure with a reduced LV ejection fraction and
died. Patients <50 years old had a lower rate of cardiac events
than those over age 50 (5.1% versus 7.5%, P = .03), with
only one myocardial infarction and no deaths.
The average MELD score in the patients with cardiac
events was 23 ± 8. This was not diﬀerent from patients who
did not have cardiac events (P = .10) regardless of type.Journal of Transplantation 3
Total OLT patients
N = 393
Remainder of OLT
patients
N = 340/393 (87%)
Medical and surgical
related deaths
N = 27/393 (6.9%)
Primary cardiac
events
N = 26/393 (6.6%)
Arrhythmias
N = 13/26 (50%)
Myocardial
infarction
N = 6/26 (23%)
New CHF
N = 7/26 (27%)
Death
N = 2/13 (15%)
Death
N = 0
Death
N = 1/7 (14%)
(a)
Total OLT patients
N = 393
Cardiac events
N = 26/393 (6.6%)
Intra-operative
N = 13/26 (50%)
Post-operative to
discharge
N = 12/26 (46%)
Discharge to 4
months post-OLT
N = 1/26 (4%)
Deaths
N = 2/13 (15%)
Deaths
N = 0
Deaths
N = 1/1 (100%)
(b)
Figure 1: (a) All mortality and type of acute cardiac events after liver transplantation. CHF: congestive heart failure and LT: liver transplant.
(b) Timing of acute cardiac events and when mortality occurred. LT: liver transplant.
Table 2: Cardiac events in the liver transplant population at MCA (N = 393).
N Events Event Rate Deaths Event Type and Period
No Death Death
IO PO PD IO PO PD
Age < 50 138 7 5% 0 4 3 0 0 0 0
No Cardiac Risk Factors 43 1 2% 0 AR: 1 0 0 0 0 0
Cardiac Risk Factors 95 6 6% 0 3 3 0 0 0 0
DSE 40 4 10% 0 AR: 3 HF: 1
No DSE 55 2 4% 0 MI: 1, HF: 1
Age > 50 255 19 8% 3 7 9 0 2 0 1
DSE 193 15 8% 2 AR: 4; MI: 1 MI: 4; HF: 3; AR: 1 0 AR: 2 0
Non-DSE stress/cath 35 4 11% 1 AR: 2 HF: 1 HF: 1
No stress test 27 0 0% 0
AR: arrhythmia, cath: cardiac catheterization, DSE: Preoperative dobutamine stress echocardiogram, HF: heart failure, IO: intraoperative, MI: myocardial
infarction, PO: perioperative period up until hospital discharge, and PD: time period from hospital discharge to 4 months posttransplant.4 Journal of Transplantation
Total OLT
patients
N = 393
Age ≥ 50
N = 255
(65%)
Age < 50
N = 138
(35%)
Arrhythmia
N = 4( 3 % )
MI
N = 1( 1 % )
New CHF
N = 2( 2 % )
Arrhythmia
N = 9( 4 % )
New CHF
N = 5( 2 % )
MI
N = 5( 2 % )
Deaths
N = 0
Deaths
N = 0
Deaths
N = 0
Deaths
N = 2 (22%)
Deaths
N = 0
Deaths
N = 1 (20%)
Figure 2: Acute cardiac events and mortality by age <50 or ≥50 years old in the LT patient study group. CHF: congestive heart failure, MI:
myocardial infarction, and LT: liver transplant.
Orthotopic liver transplant patients
1999–2007
N = 393
A g e5 0o rg r e a t e r
N = 255
Under age 50
N = 138
No cardiac risk
factors
N = 43
Risk factors
N = 95
Pre-op DSE
N = 193
Cath or
non-DSE
stress test
N = 35
No stress
test
N = 27
Cardiac events
N = 1
11 had pre-op DSE
Event rate: 2%
IO, AR: 1
Pre-op DSE
N = 40
Cardiac events
N = 4
Event rate: 10%
IO, AR: 3 HF,
PO: 1
No DSE
N = 55
Cardiac events
N = 2
Event rate: 4%
HF, PO: 1, MI,
PO: 1
Cardiac events
N = 15
Event rate: 8%
AR, IO: 6,
MI, IO:5 MI,
PO: 1
HF, PO: 3
Event rate: 11%
AR, IO: 2
HF, PO: 2
Cardiac
events
N = 0
Cardiac
events
N = 4
No deaths No deaths No deaths 2d e a t h s
AR, IO: 2
1d e a t h s
HF, PO: 1 No deaths
Figure 3: Acute cardiac events and mortality by age in the LT patient study group by age, cardiac risk factors, and results of
preoperative cardiac stress test. AR: arrhythmia, cath: cardiac catheterization, DSE: Dobutamine stress echocardiogram, HF: heart failure,
IO: intraoperative, MI: myocardial infarction, PO: perioperative period up until hospital discharge, and PD: time period from hospital
discharge to 4 months posttransplant.
In the patients >50 years old who are by AASLD guidelines
a high-risk group, 228 of 255 (89%) underwent and passed
a cardiac screening test for CAD. In patients ≤50 who were
considered high risk 40 of 95 (41%) underwent and had
negative screening dobutamine stress echo (DSE). Eleven of
43 low-risk patients ≤50 years old (26%) also had negative
DSE. There was no detectable diﬀerence in the incidence
of cardiac events between high-risk patients who had a
preoperative DSE (19 events (7.5% event rate) (N = 254))
compared with patients who did not undergo DSE testingJournal of Transplantation 5
Table 3: Cardiac events: Patient characteristics.
n 26
Age (years) 55 ± 8
Male 19 (73%)
Diabetes mellitus 6 (23%)
Hypertension 11 (42%)
History of smoking 15 (58%)
Known Coronary Artery Disease 1 (4%)
MELD score at time of transplant 23 ± 8
Cold Ischemic Time (hours) 6.0 ± 2.0
MELD: model for end stage liver disease.
(7 events (4.7% event rate) (N = 149) (P = .27)). The
relative risk of four month cardiac events for high-risk
patients by AASLD criteria compared with patients aged less
than 50 with no cardiac risk factors was 3.071 (conﬁdence
interval 0.568–17.827) (Fisher exact test P = .34) (Figure 3).
Table 3 shows the characteristics of patients who had a
cardiacevent.Themedianandaveragenumberofriskfactors
in patients who had a cardiac event (median = 1, average =
1.22 ± 0.80) did not diﬀer from those who did not (median
= 1, average = 1.03 ± 0.82) (P = .06).
5. Discussion
Acute cardiac events are recognized as an important cause
of death in patients undergoing liver transplantation [11,
12], especially in those known to have preexistent CAD.
In response, the AASLD has recommended preoperative
cardiac stress testing to detect occult CAD in “high-risk”
ESLD patients [2]. However, the scientiﬁc basis for this
recommendation remains controversial [3–6]a n dm a n y
acute cardiac events occur in patients with few CAD risk
factors and without obvious clinical, ECG, or serologic
evidence of myocardial ischemia or infarction [10].
To reexamine the relation between possible occult CAD
and acute cardiac events post-LT we reviewed the ﬁrst 393
patients who underwent LT at our institution over a 10-
year period. Because preexistent CAD is associated with
increased cardiac mortality [11] only 11/393 patients (3%)
that underwent liver transplantation had known preexistent
CAD. Of the 350 LT patients who otherwise met “high-
risk” AASLD criteria, 268 or 77% underwent a cardiac stress
or imaging study to rule out signiﬁcant coronary artery
stenosis. All patients had follow-up till four months after
their transplantation, after which many left our area and
returned home.
The principal ﬁnding in our nearly 400 liver transplant
recipients over a ten-year period is that by eliminating
patients with preexistent CAD, and screening the majority of
others with DSE, deaths due to acute, primary cardiac events
atthetimeofsurgeryanduptofourmonthspost-LTarevery
uncommon (0.8%) compared to deaths related to medical
and surgical complications (6.9%). Likewise, the overall
cardiac event rate of 7% was quite low. The 138 patients
<50 years old had an adverse event rate that was lower than
the ≥ 50 age group (5.1% versus 7.5%), and regardless of
AASLD cardiac risk factor score no fatal events occurred.
This suggests that the current AASLD recommendation that
“low-risk” patients <50 years of age could be expanded to all
individuals in this younger patient group.
Cardiac arrhythmias that caused hemodynamic instabil-
ity were included in our acute cardiac events even though
they can be precipitated by metabolic and other factors
independent of myocardial ischemia. A signiﬁcant secondary
ﬁnding in our study was that half of the 26 serious adverse
cardiac events observed were life threatening arrhythmias,
with 12 of 13 occurring in the operating room. These
arrhythmias usually occurred at the time of, or after, donor
liver reperfusion and resulted in two of the three cardiac
fatalities that occurred. These events were also seen in the
patients <50 years old, and were not predicted by the results
of preoperative DSE cardiac stress testing. Preoperative DSE
also did not predict the myocardial infarctions and new
heart failure that were also seen in fewer numbers. The
myocardial infarctions occurred immediately after surgery
and during the hospitalized period but uniformly appeared
to be small (by cardiac biomarkers and ECG ﬁndings)
suggesting they may have been due to “demand ischemia”
rather than a ruptured atherosclerotic plaque. All had a
favorable prognosis.
Although the deﬁnition of an acute cardiac event varies
in reports on the LT population, our overall incidence of
short-term acute cardiac events of 7% with a mortality of
<1% is lower than most other single-center experiences. For
instance, in 117 patients undergoing LT a high cardiac event
rate of 20% (including intraoperative hemodynamic events
and postoperative troponin elevation) has been reported
with no association between cardiac events and conventional
preoperative risk factors, including age [4]. In a large group
of LT patients studied in England between 1982 and 1998
(n = 1312), the three month incidence of cardiac events
(MI, angioplasty, coronary artery bypass grafting, or cardiac
arrest) was reported as 4.5% [13]. Recently, the incidence
of new onset systolic heart failure following LT in patients
without conventional risk factors was reported as 7% [14].
In a report from China, LT patients transplanted between
1993 to 2001 had a 7% incidence of MI and a 10% incidence
of heart failure [15]. The most likely explanation for the
low short-term cardiac event rate in the present study, and
in particular MI, may have to do with patient selection
and an aggressive DSE protocol. Nearly all patients with
known CAD were turned down as candidates and during
DSE dobutamine, ﬂuids and sometimes atropine was used
to reach a peak of >85% of maximal predicted heart rate or a
peak heart rate times systolic blood pressure of >16,000 [10].
The most important risk factorforhaving a cardiac event
with LT was being >50 years old. All three fatalities were
seen in this group. Additional AASLD cardiac risk factors
besides age did not increase the risk of cardiac events in
o u rp a t i e n t s .P r e o p e r a t i v eD S Ev e r s u sn os t r e s so ri m a g i n g
study also did not appear to relate to the incidence of cardiac
events (Figure 3). However, without randomizing patients to
haveorforegostandardizedcardiacstresstestingitisdiﬃcult
to know how important preoperative screening for occult6 Journal of Transplantation
CAD is in the LT population. It may be that eliminating
patients with known CAD who have presumably a large
atheromatous plaque burden is more eﬀective in reducing
cardiac events than screening asymptomatic patients.
Intraoperative cardiovascular arrhythmias during LT
surgery such as asystole, ventricular tachycardia, and ven-
tricular ﬁbrillation are well described, especially at the time
of or after donor liver reperfusion [5, 16–21]. Although
the causes of these events are unclear, myocardial ischemia
may not necessarily be the most common trigger. Metabolic
abnormalities, postreperfusion syndrome [16], pulmonary
artery catheter induced arrhythmias [5], a prolonged ECG
QT interval [17], or air embolus to the right heart associated
with liver manipulation [18–21] have all been implicated. In
the current study, where the incidence of “hard” ischemic
events such as MI is low, these intraoperative arrhythmias
stand out as being the most prominent cardiac events.
Potential substrate for serious cardiac arrhythmias in
the ESLD population are common [9, 17]. A prolonged
QTc on ECG in alcoholic patients with chronic liver disease
is associated with a higher incidence of sudden death [7,
22]. ECG QTc prolongation of >440ms has been reported
in 47% of patients with cirrhosis compared to only 5%
of control patients [23]. OTC prolongation and severity
of ESLD (Child-Pugh score) has been established [24],
and also related to markers of ventricular dysfunction
including plasma BNP [25]. Chronotropic incompetence, or
the inability to increase heart rate normally, is also associated
withincreasedmortalityinnon-ESLDpatients[22].Wehave
reported that chronotropic incompetence during DSE has
the strongest relation to increased risk for cardiac events
during, and in the 4 month period following LT [10].
Cardiac arrhythmias may also occur because of elec-
trolyte disturbances during liver transplantation. Hypomag-
nesemia is almost universal during LT surgery [26]a n d
hypokalemia and hypocalcemia are common [27].
Hemodynamic instability at the time of donor reperfu-
sion is also well recognized and can lead to cardiac arrest [16,
28]. This postreperfusion syndrome is deﬁned as a decrease
in heart rate and mean arterial pressure of at least 30% for
at least 60 seconds within the ﬁrst ﬁve minutes after liver
reperfusion [28]. Postreperfusion syndrome is thought to be
caused by decreased systemic vascular resistance, myocardial
depression, and blood loss [29, 30]. It is possible that this
cardiac stress might contribute to the small myocardial
biomarker release seen in LT patients which are often termed
“demand” ischemia infarcts.
6. Limitations
Data in this study is from a single institution over nearly 10
years and has been collected in a retrospective manner which
has well-recognized limitations compared to a prospective
study. The results reﬂect elimination of nearly all candidates
with known CAD which may account for our low MI and
CHF rates. Our follow-up was limited to the four month
periodafterlivertransplantationbecausethisrepresentedthe
most complete data set. Most other studies regarding cardiac
events following LT have measured long-term survivor risk.
Although our single center data provides a more uniform
approach to the LT population than a multicenter study,
some groups analyzed were relatively small increasing the
risk of sampling error. In many cases preoperative DSE did
not reach target endpoints and, therefore, could be labeled
as an inadequate stress [10]. For these reasons our results do
not help resolve the controversy of the need for, or best way
to perform a cardiac stress test in the older LT candidates.
The low overall incidence of CV events and death with a
most events being intraoperative and postoperative cardiac
arrhythmias in our population was the underappreciated
major ﬁnding in this study. This could be because many
studiesfocusonlongertermfollow-up.Detailedinformation
about the donor liver and intraoperative variables such as
ECG abnormalities, hemodynamics (especially hypotension
postreperfusion),andmedicationsusedwouldbeimportant
to better understand the causes of these serious intraopera-
tive arrhythmias.
7. Conclusion
By using the current screening strategy supported by the
AASLD, deaths due to acute, primary cardiac events at the
time of surgery and up to four months post-LT are very
uncommon when compared to deaths related to medical and
surgical complications. In patients over 50, intraoperative
arrhythmias are major causes of acute cardiac events. As
preoperative DSE cardiac stress testing did not predict these
events, further study on the factors which cause myocardial
electrical instability at the time of liver transplantation
appear warranted.
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